Evoke Total Assets from 2010 to 2025
| EVOK Stock | USD 3.76 0.12 3.09% |
Total Assets | First Reported 2011-12-31 | Previous Quarter 12.1 M | Current Value 14.2 M | Quarterly Volatility 5.5 M |
Check Evoke Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evoke Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 151.4 K, Interest Expense of 603.8 K or Selling General Administrative of 13.3 M, as well as many indicators such as Price To Sales Ratio of 0.74, Dividend Yield of 0.0 or Days Sales Outstanding of 51.81. Evoke financial statements analysis is a perfect complement when working with Evoke Pharma Valuation or Volatility modules.
Evoke | Total Assets |
Latest Evoke Pharma's Total Assets Growth Pattern
Below is the plot of the Total Assets of Evoke Pharma over the last few years. Total assets refers to the total amount of Evoke Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Evoke Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Evoke Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evoke Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 7.07 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Evoke Total Assets Regression Statistics
| Arithmetic Mean | 8,635,584 | |
| Geometric Mean | 5,465,319 | |
| Coefficient Of Variation | 69.42 | |
| Mean Deviation | 3,995,418 | |
| Median | 9,294,330 | |
| Standard Deviation | 5,994,408 | |
| Sample Variance | 35.9T | |
| Range | 24.9M | |
| R-Value | 0.17 | |
| Mean Square Error | 37.4T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | 213,432 | |
| Total Sum of Squares | 539T |
Evoke Total Assets History
Other Fundumenentals of Evoke Pharma
Evoke Pharma Total Assets component correlations
Click cells to compare fundamentals
About Evoke Pharma Financial Statements
Evoke Pharma investors utilize fundamental indicators, such as Total Assets, to predict how Evoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 8.1 M | 10.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Evoke Pharma Correlation against competitors. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share | Quarterly Revenue Growth 0.698 | Return On Assets | Return On Equity |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.